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Background: Mutations to the TSC1 and TSC2 genes cause the disease tuberous sclerosis complex. The TSC1 and
TSC2 gene products form a protein complex that integrates multiple metabolic signals to regulate the activity of
the target of rapamycin (TOR) complex 1 (TORC1) and thereby control cell growth. Here we investigate the
quaternary structure of the TSC1-TSC2 complex by gel filtration and coimmunoprecipitation.
Results: TSC1 and TSC2 co-eluted in high molecular weight fractions by gel filtration. Coimmunoprecipitation of
distinct tagged TSC1 and TSC2 isoforms demonstrated that TSC1-TSC2 complexes contain multiple TSC1 and TSC2
subunits.
Conclusions: TSC1 and TSC2 interact to form large complexes containing multiple TSC1 and TSC2 subunits.
Keywords: TSC1, TSC2, TSC1-TSC2 complex, Quaternary structureBackground
Mutations in either the TSC1 gene on chromosome
9q34 [1], or the TSC2 gene on chromosome 16p13.3 [2]
cause tuberous sclerosis complex (TSC) [3] and lym-
phangioleiomyomatosis (LAM) [4]. TSC is an autosomal
dominant disorder characterised by neurological symp-
toms, such as epilepsy and autism, and the development
of hamartomas in a variety of organs and tissues, includ-
ing the brain, skin and kidneys. LAM is a progressive
lung disease in women caused by abnormal smooth
muscle cell proliferation. The TSC1 and TSC2 gene pro-
ducts, TSC1 and TSC2, interact to form a protein com-
plex [5]. The TSC2 N-terminal region and multiple
regions of TSC1 are important for the TSC1-TSC2 inter-
action [6,7]. TSC2 contains a GTPase activating protein
(GAP) domain, and the TSC1-TSC2 complex is the GAP
for the ras homolog expressed in brain (RHEB) GTPase
[8]. RHEB-GTP activates the target of rapamycin (TOR)
complex 1 (TORC1), resulting in phosphorylation of
TORC1 targets, including p70 S6 kinase and the elong-
ation factor 4E binding proteins [9]. Although the TSC2
GAP domain is of obvious functional importance, the* Correspondence: m.nellist@erasmusmc.nl
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distribution, and reproduction in any mediumrole of TSC1 is less clear [10]. TSC1 stabilizes TSC2 [11]
and may be important for recruiting TSC2 to mem-
branes [12]. It is also possible that TSC1 facilitates the
formation of TSC1-TSC2 complexes containing multiple
TSC1 and TSC2 subunits. TSC1-TSC2 oligomers would
allow more sensitive allosteric control of TSC1-TSC2 ac-
tivity [13], as well as providing stability and protection
against denaturation [14].
Previously, to investigate the structure of the TSC1-
TSC2 complex we performed gel filtration on detergent
extracts of cultured cells, and estimated the size of the
TSC1-TSC2 complex as > 450 kDa [15]. However, we
have been unable to reproduce these results. In the
present study, gel filtration experiments using cell
extracts obtained by hypotonic lysis [12] indicate that
TSC1 and TSC2 form complexes up to ~1 MDa in size,
suggesting that our previous analysis underestimated the
size of the TSC1-TSC2 complex. In line with our new
findings and other results [5,16], immunoprecipitation
experiments indicated that TSC1-TSC2 complexes con-
tain multiple TSC1 and TSC2 subunits.
Methods
Constructs and antisera
An overview of the TSC1 and TSC2 proteins expressed
during this study is given in Additional file 1. To expressBioMed Central Ltd. This is an Open Access article distributed under the terms
(http://creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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was cloned as a NheI-KpnI fragment into pcDNA3.1/
V5-His (Invitrogen, Paisley, U.K.). The Tobacco Etch
Virus protease (AcTEV) recognition site (ENLYFQG)
was introduced by site directed mutagenesis (TSC1-
TEV-myc).
To generate V5 epitope-tagged TSC2 C-terminal trun-
cation constructs, XhoI sites were introduced into a V5-
tagged full-length TSC2 expression construct [17] by
site-directed mutagenesis. After excision of the 3' por-
tions of the TSC2 ORF with XhoI, the plasmids were re-
circularised, leaving the epitope tag in-frame with the
truncated ORF. To generate N-terminal truncations,
BamHI sites were introduced and the 5' portion of the
TSC2 ORF excised, leaving a truncated ORF with a new
translation initiation codon. Expression constructs were
derived for 3 C-terminal truncations: A614V5 (TSC2
amino acids 1 – 614, F904V5 (amino acids 1 – 904) and
A1153V5 (amino acids 1 – 1153), and 2 N-terminal
truncations: M1028V5 (amino acids 1028 – 1784) and
M1453V5 (amino acids 1453 – 1784). Other constructs
used in this study have been described elsewhere [18].
All constructs were verified by sequence analysis of the
entire ORF.
Antibodies were purchased from Cell Signaling Tech-
nology (Danvers, MA, U.S.A.) (mouse anti-myc, rabbit
anti-myc, rabbit anti-TOR, rabbit anti-TSC2, rabbit anti-
T1462 phosphorylated TSC2, rabbit anti-AKT), Roche
Molecular Biochemicals (Basel, Switzerland) (mouse
anti-GFP), Invitrogen (mouse anti-V5, mouse anti-
Xpress), Santa Cruz Biotechnology (rabbit anti-14-3-3ζ)
(Santa Cruz, CA, U.S.A.) or were described previously
[5,19]. Secondary antibodies for the infra-red detection
of blotted proteins were obtained from Li-Cor Bios-
ciences (Lincoln, NE, U.S.A.). Blotted protein levels were
estimated by near infra-red detection and quantification
on an OdysseyTM scanner (Li-Cor Biosciences).
Subcellular fractionation
HEK 293T cells were washed and scraped into ice-cold
phosphate buffered saline (PBS), pelleted by centrifuga-
tion (3000 g, 5 minutes, 4°C), resuspended in hypotonic
buffer [12](10 mM HEPES pH 7.5, 10 mM KCl, 1.5 mM
MgCl2, 0.1 mM EGTA, 20 mM NaF, plus protease inhi-
bitors (Complete EDTA-free, Roche Molecular Biochem-
icals)) and drawn repeatedly through a fine-gauge
hypodermic needle. Crude nuclei and undisrupted cells
were removed by centrifugation (3000 g, 5 minutes, 4°C)
and the supernatant was subjected to ultracentrifugation
(100 000 g, 1 hour, 4°C). The supernatant, containing
cytosolic proteins, was recovered and subjected to gel fil-
tration. The pellet was resuspended in extraction buffer
(50 mM HEPES pH 7.5, 10% v/v glycerol, 1 mM DTT,
100 mM NaCl, 10 mM NaF, 50 mM β-glycerophosphate,plus protease inhibitors (Complete, Roche Molecular
Biochemicals)) to extract additional proteins and disrupt
any weak salt-sensitive interactions. After ultracentrifu-
gation (100 000 g, 1 hour, 4°C), the supernatant (100
mM NaCl extract) was subjected to gel filtration. The
pellet was resuspended in extraction buffer containing
0.1% w/v Triton X100 and, after centrifugation at 10 000
g for 10 minutes at 4°C, the supernatant was subjected
to gel filtration.SMART gel filtration
Gel filtration was performed on the SMART fast pro-
tein liquid chromatography apparatus (GE Healthcare)
using a Superose 6 column. The column was pre-
equilibrated for 30 minutes prior to the injection of 50
μl cell extract. Flowrate was set at 50 μl/min and the
elution profile monitored at 280 nm. Elution fractions
(50 μl) were collected and analysed by immunoblotting
and compared to a series of molecular size markers:
blue dextran (2 MDa), thyroglobulin (660 kDa), ferritin
(400 kDa) and catalase (240 kDa). Gel filtration was
carried out in 50 mM HEPES pH 7.5, 1 mM DTT, 100
mM NaCl, 10 mM NaF, 50 mM β-glycerophosphate, 1
mM EDTA. For analysis of the detergent extract, 0.1%
w/v Triton X100 was included in the gel filtration
buffer.Immunoprecipitation
HEK 293T cells in 6 cm dishes were transfected with
expression constructs using polyethylenimine (Poly-
sciences Inc., Warrington, PA, U.S.A.)[20]. Twenty-four
hours after transfection the cells were washed with ice-
cold PBS and lysed in 0.3 ml lysis buffer (50 mM
HEPES pH 7.5, 10% v/v glycerol, 1 mM DTT, 100 mM
NaCl, 10 mM NaF, 50 mM β-glycerophosphate, 0.1%
Triton X100 plus protease inhibitors (Complete, Roche
Molecular Biochemicals)) for 10 minutes on ice. The
lysates were cleared by centrifugation (10 000 g for 10
minutes at 4°C).
For immunoprecipitation of myc or V5 tagged pro-
teins, EZ Red anti-myc or anti-V5 affinity beads (Sigma-
Aldrich) were pre-washed with lysis buffer and then
incubated with the cleared lysates for 3 hours at 4°C
with gentle rotation. For immunoprecipitations using
antibodies against TSC2 or the Xpress tag, the anti-
bodies were incubated with the lysates on ice for 90
minutes before transfer to pre-washed Protein A/G
beads and incubation at 4°C for 3 hours with gentle ro-
tation. Beads were washed at least 3 times with >20-fold
excess of lysis buffer per wash, recovered between each
wash by centrifugation (1000 g for 15 seconds at 4°C)
and resuspended in sample buffer prior to immunoblot
analysis.
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HEK 293T cells in 10 cm dishes were cotransfected with
the TSC2 and TSC1-TEV-myc expression constructs.
Forty-eight hours after transfection the cells were rinsed
with cold PBS and lysed in 0.4 ml of lysis buffer for 10
minutes on ice prior to centrifugation (10 000 g for 10
minutes at 4°C). The supernatant was transferred to 20
μl of a 50% suspension of EZ Red anti-myc affinity beads
(Sigma-Aldrich), pre-equilibrated with lysis buffer, and
agitated gently for 4 hours at 4°C. Beads were recovered
by centrifugation (1000 g for 15 seconds at 4°C) and
washed 3 times with 0.4 ml lysis buffer. The washed
beads were resuspended in 40 μl of lysis buffer and incu-
bated overnight at 4°C with 10U of AcTEV (Invitrogen).
Beads were removed by centrifugation (1000 g for 15
seconds at 4°C) and the supernatant fraction analysed by
gel filtration.Figure 1 Superose 6 gel filtration analysis of the TSC1-TSC2 complex.
were disrupted as described in Materials and Methods, to prepare a hypoto
TSC1, TSC2 and T1462-phosphorylated TSC2 (TSC2-T1462) in the 2 extracts
immunoblotting. (B) The cytosolic extract was applied to a Superose 6 gel
for the presence of TOR, TSC2, TSC1, AKT and 14-3-3ζ. Peak elution fraction
NaCl extract was separated and analysed as in (B), except that the elution fResults and discussion
Gel filtration of the TSC1-TSC2 complex
Previously, we estimated the size of the TSC1-TSC2
complex by gel filtration of detergent lysates of HeLa
cells [15]. TSC1 and TSC2 co-eluted at an estimated
molecular weight > 450 kDa. More recently, we repeated
these gel filtration experiments using detergent-free
extracts of human embryonal kidney (HEK) 293T cells.
Cells were first lysed in hypotonic buffer to prepare a
cytosolic extract. Subsequently, the remaining insoluble
material was extracted first with buffer containing 100
mM NaCl and finally in buffer containing 0.1% w/v Tri-
ton X100. Elution fractions of the extracts were collected
and separated by SDS-PAGE and probed for the pres-
ence of TSC1 and TSC2 by immunoblotting, as shown
in Figure 1. For comparison, and to confirm that the
lysis and gel filtration procedure gave the expected(A) Subcellular fractionation of the TSC1-TSC2 complex. HEK 293T cells
nic extract (cytosol) and a 100 mM NaCl extract. The distribution of
was compared to the proteins TOR, FMRP, AKT and 14-3-3ζ by
filtration column and the elution fractions analysed by immunblotting
s of the molecular weight standards are indicated. (C) The 100 mM
ractions were tested for FMRP instead of AKT.
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tions for TOR, AKT, FMRP and 14-3-3ζ. TSC1 and
TSC2 were present in all extracts, similar to TOR and
14-3-3ζ. In contrast, AKT was predominantly in the
cytosolic extract, as expected [21], while most FMRP
was detected in the 100 mM NaCl extract.
TSC1 (130 kDa) and TSC2 (200 kDa) co-eluted across
a broad range of fractions. For both proteins the peak
fractions were 20–24 (estimated molecular weight 900–
1200 kDa) for the cytosolic extract, and 18–22 (1100–
1400 kDa) for the 100 mM NaCl extract (Figure 1 and
Additional file 2B and E). The elution profiles for TOR
were slightly different to those for TSC1 and TSC2.
TOR eluted slightly later, with peak fractions 26–28
(600–800 kDa) for the cytosolic extract and 24–28
(600–900 kDa) for the 100 mM NaCl extract (Figure 1
and Additional file 2A and D), corresponding quite well
with previous estimates of the size of TOR complexesFigure 2 Coimmunoprecipitation of distinct epitope-tagged TSC2 isof
expressed in HEK293T cells with or without co-expressed TSC1. Distinct tag
coimmunoprecipitated tagged isoforms was investigated by immunoblotti
TSC2V5 was co-expressed with GFPTSC2 or untagged TSC2. GFPTSC2 was d
distinct from the 200 kDa TSC2 and TSC2V5 bands. TSC2V5 was immunopr
the washed beads showed that GFPTSC2 was coimmunoprecipitated with
TSC2V5. (B) Coimmunoprecipitation of TSC1 and TSC2V5 with XpTSC2. XpT
specific for the Xpress tag. The Xpress- and V5-tagged TSC2 isoforms could
antibodies. TSC2V5 coimmunoprecipitated with XpTSC2. (C) Coimmunopre
with GFPTSC2 or GFPTSC2 containing the R611Q (GFPR611Q), R905Q (GFPR
without co-expressed TSC1. As a control, GFPTSC2 was co-expressed with V
coimmunoprecipitated with TSC2V5. In contrast, GFPTSC2 was not detecte(~700 kDa) [22-24]. AKT (60 kDa) and 14-3-3ζ (30 kDa)
eluted later, with fractions 38 and 40 (< 200 kDa) show-
ing the strongest signals (Figure 1 and Additional file 2C
and F). The elution profile for FMRP had 2 distinct
peaks, corresponding to fractions 10–12 (1800–2000
kDa) and 32–34 (200–300 kDa). Most likely the FMRP
detected in fractions 10–12 corresponds to FMRP asso-
ciated with ribosomes, while the peak corresponding to
fractions 32–34 represents FMRP homo-multimers [25].
The combined molecular weight of the TSC1-TSC2
dimer is 330 kDa. Therefore, the elution profiles sug-
gested that TSC1 and TSC2 exist as subunits of larger
protein complexes, consistent with previous findings
[15,16]. TSC2 was detected in a broader range of frac-
tions than TSC1, particularly from the cytosolic extract
(Figure 1B and Additional file 2B), suggesting that a pro-
portion of the TSC2 in the cytosol is not associated with
TSC1.orms. Untagged TSC2, GFPTSC2, XpTSC2 and/or TSC2V5 were co-
ged isoforms were immunoprecipitated and the presence of other
ng. (A) Coimmunoprecipitation of TSC1 and GFPTSC2 with TSC2V5.
etectable as a 220 kDa band in immunoblots of the cell lysates,
ecipitated from the lysates with V5 affinity beads. Immunoblotting of
TSC2V5. No GFPTSC2 was immunoprecipitated in the absence of
SC2 was immunoprecipitated from cell lysates with an antibody
be distinguished by immunoblotting using the appropriate specific
cipitation of GFPTSC2 variants with TSC2V5. TSC2V5 was co-expressed
905Q) or N1620S (GFPN1620S) pathogenic substitutions, with or
5-tagged B-lactamase (lacV5). All the GFP-tagged TSC2 variants were
d in the lacV5 immunoprecipitates.
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tiple sites, including T1462, by AKT, resulting in inhi-
bition of TSC1-TSC2 complex function. It has been
proposed that AKT-dependent phosphorylation of TSC2Figure 3 Coimmunoprecipitation of distinct epitope-tagged
TSC1 isoforms. TSC1myc and TSC1V5 were co-expressed with TSC2
in HEK293T cells. The distinct tagged TSC1 isoforms were
immunoprecipitated and the presence of other
coimmunoprecipitated tagged isoforms was investigated by
immunoblotting. (A) Coimmunoprecipitation of TSC2 and TSC1myc
with TSC1V5. TSC1V5 was co-expressed with TSC2 and TSC1myc.
TSC1V5 was immunoprecipitated with anti-V5 affinity beads, washed
and the immunoprecipitates analysed by immunoblotting. TSC1myc
and TSC2 were detected in the TSC1V5 immunoprecipitate.
(B) Coimmunoprecipitation of TSC2 and TSC1V5 with TSC1myc.
TSC1myc was co-expressed with TSC2 and TSC1V5 or V5-tagged
β-lactamase (lacV5). TSC1myc was immunoprecipitated with anti-
myc affinity beads, washed and the immunoprecipitates analysed by
immunoblotting. TSC1V5 and TSC2, but not lacV5, were detected in
the TSC1myc immunoprecipitate. As an extra control, TSC2 and
TSC1V5 were co-expressed with myc-tagged β-lactamase (lacmyc),
and immunoprecipitated with anti-myc affinity beads. TSC1V5 was
not detected in the lacmyc immunoprecipitate.and subsequent binding of 14-3-3 proteins results in se-
questration of TSC1-TSC2 complexes in the cytosol
[12], and therefore in a distinct compartment from the
TSC1-TSC2 substrate RHEB which is predominantly ac-
tive on endomembranes [26]. Consistent with this idea,
we only detected T1462-phosphorylated TSC2 in frac-
tions from the cytosolic extract (Figure 1). Furthermore,
although we did not demonstrate a direct interaction be-
tween TSC2 and 14-3-3ζ, co-elution of TSC2 and 14-3-3ζ
in fractions 24–40 of both extracts (Figure 1 and Add-
itional file 2) is consistent with TSC2-14-3-3ζ binding
[27,28]. The elution profiles of TOR, AKT, FMRP and
14-3-3ζ were consistent with previous findings and
therefore it is unlikely that the apparent large size esti-
mates for the TSC1-TSC2 complex in the cytosolic and
100 mM NaCl extracts were artefacts of the lysis and
fractionation procedure.
TOR, TSC1 and TSC2 co-eluted in the early fractions
of the Triton X100 extract (Additional file 2G and H;
peak fraction 10, estimated molecular weight ~2 MDa).
One possibility is that TOR and TSC1-TSC2 complexes
associate with detergent-containing micelles. Alterna-
tively, these proteins may form very large (≥ 2 MDa), in-
soluble, membrane-associated complexes. We did not
account for the formation of these structures in our ori-
ginal investigation [15], and it is possible that this may
partly explain the differences between our previous and
current estimates for the molecular weight of the TSC1-
TSC2 complex. Nonetheless, in both cases, the esti-
mated molecular weight of the complex is greater than
could be accounted for by a 1:1 heterodimer, consistent
with the presence of multiple TSC1 and/or TSC2 sub-
units in the TSC1-TSC2 complex. Interestingly, the elu-
tion profiles of TSC1 and TSC2 are similar to those
described for the RGC1-RGC2/AS250, RalGAP1 and
RalGAP2 GAP complexes [29-31]. In each case, the ac-
tive GAP complex consists of two distinct subunits, of
which the catalytic subunit has significant homology
with the TSC2 GAP-domain [30-32]. It is possible that
such multimeric GAP complexes would be more respon-
sive allosteric regulation [13,14], and therefore more
sensitive to changes in upstream signalling events.
Next, we determined the elution profile of affinity
purified TSC1-TSC2 complexes. Coomassie staining of
the purified complex revealed equal amounts of TSC1
and TSC2 and no other major protein components
(Additional file 3), consistent with previous results [32].
Affinity purified TSC1 and TSC2 co-eluted (peak frac-
tion 20; 1200 kDa), indicating that TSC1 and TSC2 form
high molecular weight complexes in the absence of other
protein components. In agreement with a previous re-
port [16], we concluded that these complexes contain
multiple TSC1 and TSC2 subunits, possibly as many as
a 4:4 heterooctamer (predicted molecular weight 1320
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TSC2 peaks in the elution profile suggests that TSC1
and TSC2 can assemble into multiple distinct com-
plexes, containing different numbers of TSC1 and TSC2
subunits.
Coimmunoprecipitation of TSC1-TSC2 complexes
To confirm the existence of TSC1-TSC2 complexes con-
taining multiple TSC1 and TSC2 subunits, we co-
expressed distinct epitope tagged TSC1 and TSC2
isoforms and determined the composition of TSC1-
TSC2 complexes containing these isoforms by immuno-
precipitation. Immunoprecipitation of TSC2V5 with
anti-V5 antibodies resulted in coimmunoprecipitation
of GFPTSC2, as well as TSC1 (Figure 2A). Similarly,
TSC2V5 was coimmunoprecipitated with N-terminal
Xpress epitope tagged TSC2 (XpTSC2) and anti-Xpress
antibodies (Figure 2B).
Specific missense mutations in the N-terminal region of
TSC2, such as the R611Q substitution [18], disrupt theFigure 4 Coimmunoprecipitation analysis of TSC2-TSC2 interactions u
proteins were coexpressed with TSC2, or in combination. The truncated pr
detected by immunoblotting. (A) Coimmunoprecipitation of untagged, full
TSC2 proteins (A614V5, F904V5, A1153V5, M1028V5 and M1453V5; see Mate
immunoprecipitated with anti-V5 affinity beads and the washed immunop
coimmunoprecipitated with all 5 TSC2 truncation proteins, but was not vis
expressed). (B) Coimmunoprecipitation of the A1153V5 TSC2 truncation pro
M1028V5 and M1453V5. Full-length TSC2 and the M1028V5 and M1453V5 t
antibody recognising epitopes encoded by the last exon of TSC2 [5] and th
each case, the A1153V5 truncation protein was coimmunoprecipitated. No
expressing A1153V5 only (control).TSC1-TSC2 interaction. Other pathogenic TSC2 amino
acid substitutions, such as N1620S, most likely inactivate
the TSC1-TSC2 complex by altering the conformation of
the active site in the GAP domain without affecting TSC1-
TSC2 complex formation [33]. Finally, other pathogenic
mutations, such as R905Q, clearly affect TSC2 function
[34], although it is not yet clear how. We investigated
whether GFPTSC2-TSC2V5 coimmunoprecipitation was
affected by the co-expression of TSC1 or by the introduc-
tion of the pathogenic TSC2 R611Q, R905Q or N1620S
substitutions. As shown in Figure 2C, neither the absence
of TSC1, nor the introduction of the R611Q, R905Q or
N1620S mutations affected GFPTSC2-TSC2V5 coimmu-
noprecipitation. Therefore, we concluded that TSC1 is not
required for the TSC2-TSC2 interaction and that this
interaction is direct and not affected by the R611Q,
R905Q or N1620S mutations.
Over-expression of TSC1 in the absence of co-expressed
TSC2 results in the formation of large, insoluble aggre-
gates of TSC1. Co-expression of TSC2 prevents TSC1sing truncated TSC2 proteins. A series of V5-tagged TSC2 truncation
oteins were immunoprecipitated and coimmunoprecipitated proteins
-length TSC2 with TSC2 truncation proteins. The V5-tagged truncated
rials and Methods and Suppl. Figure 1. for details) were
recipitates were analysed by immunoblotting. TSC2 was
ible in the control transfection (control; no V5-tagged protein
tein with untagged TSC2 and the N-terminal TSC2 truncation proteins,
runcation proteins were immunoprecipitated with a polyclonal
e washed immunoprecipitates were analysed by immunoblotting. In
A1153V5 was visible in the immunoprecipitate of control cells,
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complexes [5,15]. To determine whether these soluble
TSC1-TSC2 complexes contain multiple TSC1 molecules,
we coexpressed TSC1 tagged with a C-terminal V5 epi-
tope (TSC1V5) and TSC1 tagged with a C-terminal myc
epitope (TSC1myc) with TSC2. Immunoprecipitation of
TSC1V5 resulted in coimmunoprecipitation of TSC1myc
and TSC2, and TSC1V5 and TSC2 were coimmunopreci-
pitated with TSC1myc (Figure 3).The N- and C- terminal regions of TSC2 are involved in
the TSC2-TSC2 interaction
To investigate the TSC1-TSC2 and TSC2-TSC2 interac-
tions in more detail, we performed coimmunoprecipita-
tion experiments using a series of truncated TSC2
proteins. Consistent with previous findings [15], we
found that the N-terminal region of TSC2 was required
for binding TSC1 (Additional file 4). TSC1myc was
coimmunoprecipitated with truncation proteins consist-
ing of TSC2 amino acids 1–614 (TSC2 A614V5),
1–904 (TSC2 F904V5) or 1–1153 (TSC2 A1153V5) but
not with truncation proteins consisting of TSC2 amino
acids 1028–1784 (TSC2 M1028V5) or 1453–1784 (TSC2
M1453V5). In contrast, TSC2 was coimmunoprecipitated
by all the TSC2 truncation proteins tested (Figure 4).
Furthermore, the A1153V5 truncation coimmunopreci-
pitated with the M1028V5 and M1453V5 truncations, in-
dicating that the N-terminal and C-terminal regions of
TSC2 are both involved in TSC2-TSC2 binding.Conclusions
We performed gel filtration and coimmunoprecipitation
experiments to investigate the quaternary structure of
the TSC1-TSC2 complex. Although we could not con-
firm our previous estimate of the size of the TSC1-TSC2
complex, our new data support the proposal that the
TSC1-TSC2 complex can contain multiple TSC1 and
TSC2 subunits [15,16]. Classical enzyme kinetic models
indicate that multimeric complexes can be very sensitive
to the effects of allosteric interactions, and therefore bet-
ter regulators [13]. A multimeric TSC1-TSC2 complex
would potentially be more responsive to changes in up-
stream signalling events than the single heterodimer.
Our data indicate that the N- and C-terminal regions
of TSC2 are involved in the TSC2-TSC2 interaction,
and that TSC1 is not required for TSC2-TSC2 binding.
Further studies will be required to elucidate the exact
nature of the inter-molecular interactions that stabilise
the TSC1-TSC2 complex, and to determine whether
oligomerisation of the TSC1-TSC2 heterodimer is im-
portant for the regulation of TORC1 signalling in nor-
mal and disease states. In particular it will be
interesting to determine whether specific, pathogenicTSC1 and TSC2 amino acid substitutions affect TSC1-
TSC2 oligomerisation.Additional files
Additional file 1: TSC1 and TSC2 truncation proteins. Schematic
diagram illustrating the epitope tagged and truncated TSC1 and TSC2
isoforms used as part of this study. The different expressed proteins are
represented by bars scaled according to the number of encoded amino
acids, compared to the untagged isoforms (top). GFP, Xpress (Xp), myc
and V5 epitope tags are represented by solid (filled) regions at either
the amino- (N) or carboxy- (C) terminal of the full-length and truncated
proteins. The most C-terminal amino acids are indicated above the bars.
(A) Epitope-tagged and truncated TSC2 isoforms. The position of the
TSC2 GAP domain is indicated. The positions of the amino acid
substitutions in the GFPTSC2 isoform, and the initiation methionines for
the 2 N-terminal TSC2 truncation proteins are shown above the bars.
(B) Epitope-tagged TSC1 isoforms. The positions of the putative
transmembrane domain and coiled coil region are indicated. The
location of the AcTEV endonuclease cleavage site is shown (AcTEV).
Additional file 2: Overview of the Superose 6 gel filtration
experiments. The integrated intensities of the protein bands in the
different elution fractions were determined in 3 separate immunoblot
experiments. The total signal per protein was determined and the
relative signal per fraction was calculated. Elution profiles for TOR (A, D
and G), TSC1 and TSC2 (B, E and H), AKT (C), FMRP (F) and 14-3-3ζ
(C and F) from the cytosolic (A - C), 100 mM NaCl (D - F) and 0.1%
Triton X100 (G - H) extracts are shown. Peak elution fractions of the
molecular weight standards are indicated. Error bars show the standard
error of the mean.
Additional file 3: Superose 6 gel filtration of affinity purified
TSC1-TSC2 complexes. (A) TSC1-TSC2 complexes released from anti-myc
affinity beads by AcTEV endonuclease digestion (see Materials and
Methods for details) were resolved by SDS-PAGE and detected by
Coomassie staining. Approximately equal quantities of both proteins
were visible on the gels, and no other major protein components (>50
kDa in size) were detected. (B) The purified TSC1-TSC2 complexes were
applied to the Superose 6 column and the elution fractions analysed by
immunblotting. Peak elution fractions of the molecular weight standards
are indicated. (C and D) Elution profiles for TSC2 (C) and TSC1 (D). The
integrated intensity of the protein bands were determined per fraction.
The peak elution fractions of the molecular weight standards are
indicated.
Additional file 4: Coimmunoprecipitation of TSC1with the N-
terminal of TSC2. TSC1 was co-expressed with TSC2V5, the TSC2
truncation proteins (A614V5, F904V5, A1153V5, M1028V5 and M1453V5),
V5-tagged β-lactamase (lacV5), or empty vector (control). The V5-tagged
proteins were immunoprecipitated with anti-V5 affinity beads and the
washed immunoprecipitates were analysed by immunoblotting. TSC1
was coimmunoprecipitated with TSC2V5 and with the C-terminal
truncation proteins A614V5, F904V5 and A1153V5 (encoding amino acids
1–614, 1–904 and 1–1153 respectively), but not with the N-terminal
truncation proteins M1028V5 and M1453V5 (encoding amino acids
1028–1784 and 1453–1784, respectively), or lacV5.Abbreviations
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